文献速递泌尿生殖MRUS

前列腺MRI/超声融合活检与系统性前列腺活检的比较——联合方法在日常临床实践中的有效性和准确性

MRI/ultrasound fusion biopsy of the prostate compared to systematic prostate biopsy - Effectiveness and accuracy of a combined approach in daily clinical practice.
PubMed 文献 · Eur J Radiol · 2022-07-02

该回顾性单中心研究纳入2015年10月至2018年12月524例联合活检病例,比较融合引导靶向活检与系统12针活检的癌症检出率。联合活检检出癌症270/524(51.5%);融合引导活检单独检出227/524(43.3%)、临床显著癌150/524(28.6%),系统活检单独检出205/524(39.1%)、临床显著癌137/524(26.1%)。结论认为融合引导活检较系统活检可检出更多前列腺癌(尤其临床显著癌),两者联合可提高检出率。

要点

  • 联合活检癌症检出率51.5%(270/524),融合引导活检单独检出43.3%(227/524),系统活检单独检出39.1%(205/524)。
  • 融合引导活检检出临床显著癌28.6%(150/524),系统活检检出26.1%(137/524)。
  • 仅融合引导活检检出者占全部阳性病例24.1%(65/270),仅系统活检检出者占15.9%(43/270)。

核心结论

  • 融合引导活检较系统活检可检出更多前列腺癌,尤其临床显著癌;两者联合可提高检出率并有助于识别临床显著癌。

研究设计与样本

  • 回顾性单中心研究,纳入2015年10月至2018年12月524例联合活检病例;所有患者因PSA升高和/或直肠指检可疑而行多参数MRI(由6名经验丰富放射科医师之一判读),随后在同一泌尿科由5名经验丰富泌尿科医师之一行融合引导活检并紧接着行系统12针活检。

诊断标准与关键数值

  • 联合活检检出癌症270/524(51.5%)。
  • 系统活检单独检出癌症205/524(39.1%),临床显著癌137/524(26.1%)。
  • 融合引导活检单独检出癌症227/524(43.3%),临床显著癌150/524(28.6%)。
  • 融合引导活检使Gleason评分组织学升级20/270(7.4%),系统活检使31/270(11.5%)。
  • 全部阳性病例中仅融合引导活检检出65/270(24.1%),仅系统活检检出43/270(15.9%)。

临床应用与阅片要点

  • 原文结论认为融合引导活检可检出更多前列腺癌(尤其临床显著癌),但两种方法联合可提高检出率并有助于识别临床显著癌。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: The aim of this study was to compare cancer detection by targeted fusion-guided biopsy with systematic biopsy, and to evaluate the value of combined biopsy, in a daily clinical practice scenario. Furthermore, we aimed to assess the influence of previous biopsies on cancer detection.

METHODS: In this retrospective single-centre study, we evaluated 524 cases of combined biopsy of the prostate from October 2015 to December 2018. All men had a clinical suspicion for prostate cancer due to an elevated PSA and/or a suspicious digital rectal examination and underwent a multiparametric MRI of the prostate read by one out of 6 experienced radiologists. In all cases, fusion-guided biopsy of the prostate was consecutively followed by systematic 12-core biopsy in the same session at the same urological department performed by one out of 5 experienced urologists.

RESULTS: In 270/524 (51.5%) cases, cancer was found using combined biopsy. Systematic biopsy alone detected cancer in 205/524 (39.1%) and clinically significant cancer in 137/524 (26.1%) cases. Fusion-guided biopsy alone detected 227/524 (43.3%) and clinically significant cancer in 150/524 (28.6%) cases. A histological upgrade of the Gleason score by fusion-guided biopsy was noted in 20/270 (7.4%) of all cancers found and by systematic biopsy in 31/270 (11.5%). Of all positive cases (clinically insignificant and significant cancer), 65/270 (24.1%) were detected only by fusion-guided biopsy, whereas 43/270 (15.9%) were detected only by systematic biopsy.

CONCLUSIONS: Fusion-guided biopsy can detect more cases of prostate cancers than systematic biopsy alone, especially clinically significant cancer. However, the combination of both biopsy methods improves the detection rate and can help to identify clinically significant cancer.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Dorfinger, Ponholzer, Stolzlechner, et al. MRI/ultrasound fusion biopsy of the prostate compared to systematic prostate biopsy - Effectiveness and accuracy of a combined approach in daily clinical practice. Eur J Radiol. 2022. PMID: 35839747. doi:10.1016/j.ejrad.2022.110432

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。